Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) CFO Sells $88,921.80 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth sold 8,910 shares of the stock in a transaction on Friday, November 21st. The shares were sold at an average price of $9.98, for a total value of $88,921.80. Following the completion of the sale, the chief financial officer owned 110,026 shares of the company’s stock, valued at $1,098,059.48. The trade was a 7.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Entrada Therapeutics Trading Down 0.4%

Shares of TRDA stock opened at $10.08 on Thursday. The company has a market capitalization of $385.26 million, a price-to-earnings ratio of -4.05 and a beta of -0.08. Entrada Therapeutics, Inc. has a 1-year low of $4.93 and a 1-year high of $21.79. The stock’s fifty day simple moving average is $6.92 and its 200-day simple moving average is $6.72.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.02). The business had revenue of $1.61 million for the quarter, compared to analyst estimates of $8.62 million. Entrada Therapeutics had a negative return on equity of 26.42% and a negative net margin of 168.16%. On average, sell-side analysts predict that Entrada Therapeutics, Inc. will post 1.12 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on TRDA shares. Roth Capital set a $13.00 target price on shares of Entrada Therapeutics in a research report on Thursday, November 6th. Wall Street Zen lowered Entrada Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Entrada Therapeutics in a research report on Wednesday, October 8th. Finally, Zacks Research raised Entrada Therapeutics to a “hold” rating in a research report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $20.67.

Institutional Investors Weigh In On Entrada Therapeutics

A number of large investors have recently bought and sold shares of the business. Merck & Co. Inc. acquired a new position in Entrada Therapeutics during the first quarter worth $15,728,000. Wellington Management Group LLP boosted its stake in shares of Entrada Therapeutics by 2.1% during the 1st quarter. Wellington Management Group LLP now owns 1,053,314 shares of the company’s stock worth $9,522,000 after acquiring an additional 21,488 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Entrada Therapeutics by 391.2% during the 3rd quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock valued at $4,852,000 after acquiring an additional 666,287 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Entrada Therapeutics by 7.2% in the 2nd quarter. Geode Capital Management LLC now owns 631,554 shares of the company’s stock valued at $4,245,000 after acquiring an additional 42,479 shares in the last quarter. Finally, Royce & Associates LP lifted its holdings in Entrada Therapeutics by 54.8% in the 3rd quarter. Royce & Associates LP now owns 345,507 shares of the company’s stock worth $2,004,000 after purchasing an additional 122,256 shares during the last quarter. 86.39% of the stock is currently owned by institutional investors.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.